Posted on by sciencefatherLeave a Comment on Nazia chaudhary | Cancer Biology | Best Researcher Award
86 / 100
Powered by Rank Math SEO

Dr. Nazia chaudhary | Cancer Biology | Best Researcher Award

Dr. Nazia chaudhary, ACTREC, TMC, India

Dr. Nazia S. Chaudhary is a DST Inspire Faculty at ACTREC-TMC, recognized for her groundbreaking work in cancer research. She earned her Ph.D. in 2022 from ACTREC (HBNI) and holds an M.Sc. from St. Xavier’s College, Mumbai. Her research focuses on tumorigenesis, chemo-radio resistance, and therapeutic vulnerabilities, with significant contributions to colorectal and breast cancer studies. Dr. Chaudhary has co-authored numerous high-impact publications and holds patents on therapeutic antibodies. She has presented her work at prestigious conferences globally and received accolades, including the DST Inspire Faculty Award and recognition for excellence in biological sciences.

Author Profile:

🎓 Education:

Dr. Nazia S. Chaudhary holds a Ph.D. in Cancer Biology from ACTREC (Homi Bhabha National Institute), which she completed in 2022. Her doctoral research explored critical aspects of tumorigenesis, chemo-radio resistance, and therapeutic vulnerabilities in cancer. Prior to her Ph.D., she earned her M.Sc. in Life Sciences from St. Xavier’s College, Mumbai, where she developed a strong foundation in molecular and cellular biology. Dr. Chaudhary’s academic journey has been marked by exceptional performance, laying the groundwork for her impactful research career. Her educational achievements reflect her dedication to advancing scientific knowledge in cancer biology and therapeutic innovation.

💼 Professional Experience:

Dr. Nazia S. Chaudhary is a DST Inspire Faculty at ACTREC-TMC, where she leads innovative research in cancer biology. She completed her Ph.D. in 2022 from ACTREC (HBNI), focusing on tumorigenesis and therapeutic resistance mechanisms. Dr. Chaudhary has extensive experience in identifying chemo-radio resistance pathways and exploring therapeutic vulnerabilities in colorectal and breast cancers. Her professional expertise spans molecular oncology, antibody development, and translational research, leading to impactful publications and patents. She has presented her findings at leading international conferences and collaborates with multidisciplinary teams to advance cancer therapeutics. Her work has earned her prestigious awards and recognition.

🌍Research Contributions:

Dr. Nazia S. Chaudhary has made significant contributions to cancer research, particularly in understanding tumorigenesis, chemo-radio resistance, and therapeutic vulnerabilities. Her work has advanced knowledge of colorectal and breast cancers, identifying novel molecular mechanisms that drive cancer progression and resistance to therapies. She has co-authored numerous high-impact publications in reputed journals, showcasing her innovative findings. Dr. Chaudhary’s research has led to patents on therapeutic antibodies, offering potential breakthroughs in targeted cancer treatments. Her contributions have been presented at renowned international conferences, reflecting her commitment to advancing cancer biology and developing effective therapeutic strategies for improved patient outcomes.

🥇Award and Honors:

Dr. Nazia S. Chaudhary has received numerous awards and honors for her outstanding contributions to cancer research. She was honored with the prestigious DST Inspire Faculty Award for her innovative work in tumor biology and therapeutic strategies. Her exceptional research has earned recognition at national and international platforms, including accolades for excellence in biological sciences. Dr. Chaudhary’s groundbreaking discoveries in chemo-radio resistance and therapeutic vulnerabilities have been acknowledged through awards at esteemed conferences and institutions. She also holds patents for therapeutic antibodies, reflecting her pioneering contributions to cancer therapeutics and her commitment to advancing translational research.

Conclusion:

Dr. Nazia S. Chaudhary’s exemplary contributions to cancer research have advanced our understanding of tumor biology, therapeutic resistance, and targeted interventions. Her innovative work on colorectal and breast cancer, coupled with her patents on therapeutic antibodies, highlights her dedication to developing effective treatment strategies. With a strong publication record and international recognition, Dr. Chaudhary continues to push the boundaries of cancer research, addressing critical challenges in oncology. Her achievements serve as a testament to her scientific excellence, making her a leading figure in the field and inspiring future advancements in cancer therapeutics and precision medicine.

📚Publication Top Notes:

Lipocalin 2 expression promotes tumor progression and therapy resistance by inhibiting ferroptosis in colorectal cancer
International Journal of Cancer 149(7), 1495-1511, 135 citations, 2021 📈🧬

Plakophilin3 loss leads to an increase in lipocalin2 expression, which is required for tumour formation
Experimental Cell Research 369(2), 251-265, 25 citations, 2018 🔬🧪

Thermophilic actinomycetes from hot water spring capable of producing enzymes of industrial importance
Int J Res Stud Biosci 4, 29-35, 15 citations, 2016 🌿🌡️

Tumor-specific overexpression of histone gene, H3C14 in gastric cancer is mediated through EGFR-FOXC1 axis
Biochimica et Biophysica Acta (BBA)-Gene Regulatory Mechanisms 1864(4-5), 2021, 14 citations 🔬🧬

Lipocalin 2 inhibits actin glutathionylation to promote invasion and migration
FEBS Letters 597(8), 1086-1097, 4 citations, 2023 ⚡🔬

Spatial Epidemiology of Signet-ring Cell Colorectal Cancer in India
Saudi Journal of Medicine & Medical Sciences 12(1), 71-75, 3 citations, 2024 🌍📊

Plakophilin3 loss leads to an increase in autophagy and radio-resistance
Biochemical and Biophysical Research Communications 620, 1-7, 3 citations, 2022 🔄📉

LCN2 and colon cancer—Have we hit the jackpot.
Journal of Clinical Oncology 38(15_suppl), e15608-e15608, 2 citations, 2020 🎯🔬

Elevated translationally controlled tumour protein promotes oral cancer progression and poor outcome
Journal of Oral Pathology & Medicine 52(9), 849-859, 1 citation, 2023 🦷🦠

EGFR-to-Src family tyrosine kinase switching in proliferating-DTP TNBC cells creates a hyperphosphorylation-dependent vulnerability to EGFR TKI
bioRxiv, 2023.07.17.549374, 1 citation, 2023 🔬⚡

GPX4-VIM equates a proliferating DTP state in TNBC subtypes with converged vulnerabilities to autophagy and glutathione inhibition
bioRxiv, 2023.05.18.541287, 1 citation, 2023 🔬🔑

Nazia chaudhary | Cancer Biology | Best Researcher Award

You May Also Like

Leave a Reply

Your email address will not be published. Required fields are marked *